![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Issues Draft Guidance for Developing Hemorrhoids Treatments
FDA Issues Draft Guidance for Developing Hemorrhoids Treatments
December 19, 2019
The FDA has recommended using increased patient input in a new draft guidance on developing corticosteroid hemorrhoid treatments.
The guidance calls on sponsors to select patient-reported outcome (PRO) instruments that will measure what patients say are their most troublesome symptoms. The FDA encouraged sponsors to use existing PRO instruments rather than develop new ones.
Comments on the draft guidance are due by Feb. 7, 2020.
Upcoming Events
-
21Oct